Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Lifted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 133.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,383 shares of the company’s stock after purchasing an additional 3,077 shares during the period. Tower Research Capital LLC TRC’s holdings in Voyager Therapeutics were worth $31,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its position in shares of Voyager Therapeutics by 24.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock valued at $7,828,000 after purchasing an additional 275,571 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth approximately $746,000. ADAR1 Capital Management LLC boosted its position in Voyager Therapeutics by 212.0% during the fourth quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company’s stock valued at $719,000 after purchasing an additional 86,158 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Voyager Therapeutics during the 4th quarter valued at about $267,000. Finally, Barclays PLC boosted its holdings in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after purchasing an additional 37,398 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on VYGR. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group cut their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $13.39.

Insider Buying and Selling

In related news, CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.39% of the stock is currently owned by corporate insiders.

Voyager Therapeutics Price Performance

VYGR stock opened at $3.28 on Friday. The stock has a market capitalization of $181.50 million, a price-to-earnings ratio of 4.62 and a beta of 0.95. The business’s fifty day moving average price is $3.45 and its two-hundred day moving average price is $4.84. Voyager Therapeutics, Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. Research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.